Tarcocimab

Summary

Tarcocimab (CHEMBL5314617) is a phase-3 clinical-stage antibody; indicated across 3 conditions including diabetic retinopathy and vascular disorder.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Antibody
• Indications: 3 conditions
• Clinical trials: 1

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL5314617
Name	Tarcocimab
Type	Antibody
Max phase	3

Also known as: OG-1950, OG1950, Tarcocimab, TARCOCIMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
diabetic retinopathy	1	MONDO:0005266	EFO:0003770
vascular disorder	1	MONDO:0005385	EFO:0004264
wet macular degeneration	1	MONDO:0005417	EFO:0004683

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06270836	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Diabetic Retinopathy (DR)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).